The direct inhibition of CCL4 modified metabolic profiles, inhibited vascular inflammation, reduced the plaque area, and promoted a relatively stable plaque phenotype in an experimental model of atherosclerosis in vivo. The gene discussed is CCL4; the disease is atherosclerosis.